Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib Plus Digoxin in BRAF Wild-type Melanoma
NCT02138292Phase 1Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Jul 2014
- Primary completion
- Feb 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of digoxin in melanoma, sponsored by UT Southwestern Medical Center. Primary endpoint: Dose Limiting Toxicities at 8 weeks. Started Jul 2014; status: completed.
02
Drugs
digoxin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02138292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138292.